How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comRole of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies
Description:
This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.
Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase:
N/A
Contacts:
Xiao Chen, Ph.D (Principal Investigator)xiaochen229@foxmail.com
+8615922970174
Government Study Link:
NCT06287411 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience